An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024.
For both companies, our main priority is ensuring you have continuous supply of Increlex throughout the transition. For more information, please contact www.ipsenmedicalinformation.com.
